埃克替尼联合TP方案治疗非小细胞肺癌的效果及对血清KIFC1、N-cadherin表达的影响  

The effect of icotinib combined with TP regimen in the treatment of non-small cell lung cancer and its influence on the expression of serum KIFC1 and N-cadherin

作　　者：姜伟华[1] 高永山[1] 刘娜 张媛[2] 杨燕君[1] 王贵刚[1] 董跃华[1] 张振明[1] JIANG Weihua;GAO Yongshan;LIU Na;ZHANG Yuan;YANG Yanjun;WANG Guigang;DONG Yuehua;ZHANG Zhenming(Department of Thoracic Surgery,the First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei 075000,China;Operating Room,the First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei 075000,China)

机构地区：[1]河北北方学院附属第一医院胸外科,河北张家口075000 [2]河北北方学院附属第一医院手术室,河北张家口075000

出　　处：《国际检验医学杂志》2022年第8期962-966,972,共6页International Journal of Laboratory Medicine

基　　金：张家口市市级科技计划(2021072D);河北省医学科学研究课题(20211359)。

摘　　要：目的探究埃克替尼联合TP方案治疗非小细胞肺癌(NSCLC)的效果及对血清驱动蛋白超家族蛋白C1(KIFC1)、N-钙黏蛋白(N-cadherin)表达的影响。方法选取2018年12月至2020年12月该院NSCLC患者108例进行前瞻性研究,以随机数字表法按1∶1比例分为观察组、对照组,各54例。对照组予以TP方案治疗,观察组予以埃克替尼联合TP方案治疗。对比两组疗效、不良反应总发生率、生活质量状况及治疗前后免疫功能[树状突细胞(DC)、DC/单核巨噬细胞(PBMC)、T细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))]、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)、鳞状细胞癌相关抗原(SCC-Ag)]、KIFC1、N-cadherin水平。结果观察组疾病控制率(75.93%)高于对照组(57.41%),差异有统计学意义(P<0.05)。观察组治疗后DC、DC/PBMC、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组(P<0.05)。观察组治疗后血清CEA、CA125、CYFRA21-1、SCC-Ag水平均低于对照组(P<0.05)。观察组治疗后血清KIFC1、N-cadherin水平低于对照组(P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。观察组生活质量增加稳定率高于对照组,差异有统计学意义(P<0.05)。结论埃克替尼联合TP方案治疗NSCLC患者,可调节血清KIFC1、N-cadherin表达,改善免疫功能,降低血清肿瘤标志物水平,提高生活质量,疗效显著,且安全性高。Objective To explore the effect of icotinib combined with TP regimen in the treatment of non-small cell lung cancer(NSCLC)and its effect on the expression of serum kinesin superfamily protein C1(KIFC1)and N-cadherin(N-cadherin).Methods From December 2018 to December 2020,108 patients with NSCLC in a hospital were selected for prospective study.They were divided into observation group and control group at a ratio of 1∶1 by random number table method,with 54 cases in each group.The control group was treated with TP regimen,and the observation group was treated with icotinib combined with TP regimen.The efficacy,total incidence of adverse reactions,quality of life and immune function before and after treatment were compared between the two groups[dendritic cells(DC),DC/mononuclear macrophages(PBMC),T cell subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))],serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment(CYFRA21-1),squamous cell carcinoma-associated antigen(SCC-Ag)],KIFC1,N-cadherin level.Results The disease control rate of observation group(75.93%)was higher than that of control group(57.41%),and the difference was statistically significant(P<0.05).After treatment,the levels of DC,DC/PBMC,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the observation group were higher than those in the control group(P<0.05).Serum levels of CEA,CA125,CYFRA21-1,and SCC-Ag in the observation group after treatment were significantly lower than those in the control group(P<0.05).Serum KIFC1 and N-cadherin levels in the observation group were lower than those in the control group after treatment(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The stable rate of increase in quality of life of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion Icotinib combined with TP regimen in the treatment of NSCLC patients can regulate the expression of serum KIFC1 and N

关 键 词：埃克替尼 TP方案 非小细胞肺癌 驱动蛋白超家族蛋白C1 N-钙黏蛋白 

分 类 号：R734.2[医药卫生—肿瘤]